Are Analysts Bullish Celgene Corporation (NASDAQ:CELG) After Last Week?

Celgene Corporation (NASDAQ:CELG) Logo
Investors sentiment increased to 0.76 in 2019 Q1. Its up 0.12, from 0.64 in 2018Q4. It improved, as 108 investors sold Celgene Corporation shares while 441 reduced holdings. 204 funds opened positions while 213 raised stakes. 482.72 million shares or 1.75% less from 491.33 million shares in 2018Q4 were reported.
Appleton Prtn Ma has 9,464 shares for 0.12% of their portfolio. Kings Point Cap Mngmt reported 400 shares. First Hawaiian National Bank & Trust invested in 17,623 shares or 0.09% of the stock. Jefferies Group Incorporated Limited Com holds 0.18% in Celgene Corporation (NASDAQ:CELG) or 234,227 shares. Private Advsr invested 0.06% in Celgene Corporation (NASDAQ:CELG). Asset One Company holds 334,165 shares. Manchester accumulated 9,768 shares. Avalon Advsrs Ltd Liability Corp holds 4,880 shares. 8,490 are owned by Rampart Investment Company Ltd Liability Corp. Tci Wealth accumulated 0.07% or 1,581 shares. Perigon Wealth Limited Liability Corporation invested in 31,954 shares. Tortoise Inv Mgmt Ltd Liability Co invested 0.01% in Celgene Corporation (NASDAQ:CELG). Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0.18% invested in Celgene Corporation (NASDAQ:CELG) for 207,933 shares. Cannell Peter B & owns 1.02M shares. Pekin Hardy Strauss owns 3,220 shares.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 5 analysts covering Celgene (NASDAQ:CELG), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Celgene has $103 highest and $95 lowest target. $100.20’s average target is 7.38% above currents $93.31 stock price. Celgene had 16 analyst reports since February 26, 2019 according to SRatingsIntel. Cantor Fitzgerald maintained it with “Hold” rating and $100 target in Monday, June 24 report. Robert W. Baird maintained Celgene Corporation (NASDAQ:CELG) on Tuesday, March 12 with “Buy” rating. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, February 28. Mizuho maintained the stock with “Buy” rating in Monday, June 24 report. The rating was maintained by Robert W. Baird on Thursday, February 28 with “Buy”. The company was maintained on Thursday, February 28 by Jefferies. Below is a list of Celgene Corporation (NASDAQ:CELG) latest ratings and price target changes.

24/06/2019 Broker: Mizuho Rating: Buy New Target: $103 Maintain
24/06/2019 Broker: Cantor Fitzgerald Rating: Hold New Target: $100 Maintain
03/05/2019 Broker: BidaskScore Rating: Hold Upgrade
03/05/2019 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Downgrade
26/04/2019 Broker: BidaskScore Rating: Sell Downgrade
05/04/2019 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Neutral Downgrade
01/04/2019 Broker: Bernstein Old Rating: Outperform New Rating: Market Perform Downgrade
01/04/2019 Broker: UBS Old Rating: Buy New Rating: Neutral Downgrade
01/04/2019 Broker: Atlantic Securities Old Rating: Overweight New Rating: Neutral Downgrade
26/03/2019 Broker: Canaccord Genuity Rating: Hold Maintain

The stock increased 0.45% or $0.42 during the last trading session, reaching $93.31. About 2.19 million shares traded. Celgene Corporation (NASDAQ:CELG) has risen 3.32% since August 15, 2018 and is uptrending. It has outperformed by 3.32% the S&P500.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $66.13 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 12.75 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Nasdaq.com which released: “Why Celgene (CELG) Could Beat Earnings Estimates Again – Nasdaq” on July 17, 2019, also Nasdaq.com with their article: “3 Top Biotech Stocks to Buy Right Now – Nasdaq” published on July 29, 2019, Nasdaq.com published: “After-Hours Earnings Report for July 30, 2019 : AAPL, AMGN, GILD, MDLZ, CELG, PSA, AMD, ALL, EQR, OKE, EA, VRSK – Nasdaq” on July 30, 2019. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Nasdaq.com and their article: “Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG’s Otezla Label Expanded – Nasdaq” published on July 24, 2019 as well as Nasdaq.com‘s news article titled: “Top Stock Reports: Micron, Sinopec, Celgene & More – Nasdaq” with publication date: August 13, 2019.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.